UNIPHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.35 TWD | 0.00% |
|
-0.37% | -9.80% |
| Apr. 24 | UniPharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | UniPharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 128M 3.97M | Sales 2023 | 103M 3.2M | Capitalization | 525M 16.29M |
|---|---|---|---|---|---|
| Net income 2022 | -6M -186K | Net income 2023 | -21M -651K | EV / Sales 2022 | 3.06 x |
| Net cash position 2022 | 159M 4.92M | Net cash position 2023 | 167M 5.17M | EV / Sales 2023 | 3.47 x |
| P/E ratio 2022 |
-85.3
x | P/E ratio 2023 |
-24.1
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 49.78% |
More Fundamentals
* Assessed data
More news
| 1 week | -0.37% | ||
| Current month | +2.30% | ||
| 1 month | +6.37% | ||
| 3 months | +1.14% | ||
| 6 months | -16.56% | ||
| Current year | -9.80% |
1 week
12.50
13.45
1 month
12.2514.35
Current year
12.0014.85
1 year
12.0021.50
3 years
10.4530.60
5 years
6.1993.00
10 years
6.1993.00
| Managers | Title | Age | Since |
|---|---|---|---|
Liang Kuang Lin
CEO | Chief Executive Officer | - | 05-07-24 |
Hui Ling Chen
DFI | Director of Finance/CFO | - | 14-10-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheng Chen
CHM | Chairman | 69 | 15-06-04 |
Liang Kuang Lin
CEO | Chief Executive Officer | - | 05-07-24 |
Chia Lin Wang
BRD | Director/Board Member | - | 17-06-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 13.35 | 0.00% | 1,165 |
| 24-05-20 | 13.35 | +0.75% | 12,207 |
| 24-05-17 | 13.25 | +0.38% | 52,208 |
| 24-05-16 | 13.2 | -0.75% | 71,391 |
| 24-05-15 | 13.3 | -0.75% | 19,808 |
End-of-day quote Taipei Exchange, May 20, 2024
More quotes
UNI PHARMA CO., LTD. is a Taiwan-based company maily engaged in wholesale of diagnostdic reagents, medical equipment and medicines. The Company's main products include Onko-SureDR-70, for monitoring and marking after Colorectal cancer surgery;Cervi-M, using in detection of DNA methylation for Cervical cancer; EZ Detect, home use fecal occult blood test paper;RFA, cancer treatment medical equipment;Bain inj, a kind of morphine analgesics;Naloxone inj, antidote for morphine drugs overdose;Esmolol inj, ultrashort type B sympathetic nerve blockers;Fomepizole inj, a kind of alcoholic poisoning antidote;and Tambocor tab, a kind of arrhythmia treatment.
| 1st Jan change | Capi. | |
|---|---|---|
| -9.80% | 14.67M | |
| -14.08% | 271M | |
| +5.27% | 190M | |
| +26.13% | 77.74M |
- Stock Market
- Equities
- 6621 Stock
